Escolhas terapêuticas iniciais para a hipertensão arterial na Rede de Médicos Sentinela by Pinto, Daniel et al.
Rev Port Cardiol. 2018;37(8):657--663
www.revportcardiol.org
Revista Portuguesa de
Cardiologia
Portuguese Journal of Cardiology
ORIGINAL ARTICLE
Initial  therapeutic choices  for  hypertension in  the
Portuguese Sentinel Practice Network
Daniel Pinto a,∗,  Ana Paula Rodriguesb, Baltazar Nunesb
a Family  Medicine  Unit,  NOVA  Medical  School,  Lisbon,  Portugal
b Department  of  Epidemiology,  Dr.  Ricardo  Jorge  National  Institute  of Health,  Lisbon,  Portugal
Received  20  August  2017;  accepted  8  October  2017
Available  online  17  July  2018
KEYWORDS
Hypertension;
Antihypertensive
agents;
Drug  utilization;
Primary  care;
Sentinel  surveillance
Abstract
Introduction  and  Objectives: Finding  out  which  drugs  are  chosen  to  treat  incident  cases  of
hypertension  may  help  in interpreting  prevalent  use  of  antihypertensive  agents.  We  aimed  to
determine  the proportion  of  patients  who  begin  treatment  with  each  antihypertensive  drug
class, which  physicians  initiate  treatment  and  whether  family  physicians  alter  prescriptions
initiated by  others,  and  to  compare  the  prescribing  patterns  of  family  physicians  and  other
specialists.
Methods:  In  this  cohort-nested  cross-sectional  study  between  2014  and  2015  within  the Por-
tuguese Sentinel  Practice  Network,  family  physicians  notified  incident  cases of  hypertension,
reporting treatment,  who  issued  the  initial  prescription  and  whether  treatments  initiated  by
other  physicians  were  changed.
Results:  A total  of  681 incident  cases  were  notified.  The  initial  prescription  was  issued  by  the
patient’s family  physician  in  86.9%  of  cases  (95%  CI: 84.2-89.3%).  The  most  frequently  used
agents were  angiotensin-converting  enzyme  inhibitors  (51.3%  of  patients,  95%  CI:  47.5-55.0%),
thiazide and  thiazide-like  diuretics  (32.2%,  95%  CI: 28.8-35.8%),  and  angiotensin  receptor  block-
ers (21.4%,  95%  CI:  18.5-24.7%).  Compared  to  other  specialists,  family  physicians  used  less
beta-blockers  (20.4  vs.  5.9%,  p<0.001)  and  loop  diuretics  (8.2  vs.  0.8%,  p=0.003).  Prescriptions
initiated by  other  specialists  were  changed  by  family  physicians  in  11.6%  of  cases  (95%  CI:
6.0-19.6%).
Conclusion:  Angiotensin-converting  enzyme  inhibitors  were  the  most  frequently  prescribed
antihypertensive  class.  Most  diagnoses  were  made  by  the  patient’s  own family  physician.  Pre-
scriptions initiated  by  other  specialists  were  usually  continued  by  family  physicians.  Prescribing
patterns were  similar  between  family  physicians  and  other  specialists,  except  for  lower  use  of
beta-blockers  and  loop  diuretics.
© 2018  Sociedade  Portuguesa  de Cardiologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
∗ Corresponding author.
E-mail address: daniel.pinto@nms.unl.pt (D. Pinto).
https://doi.org/10.1016/j.repc.2017.10.016
0870-2551/© 2018 Sociedade Portuguesa de Cardiologia. Published by  Elsevier España, S.L.U. All rights reserved.
Document downloaded from http://www.elsevier.es, day 14/10/2018. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
658  D. Pinto  et al.
PALAVRAS-CHAVE
Hipertensão  arterial;
Anti-hipertensores;
Utilização de
medicamentos;
Cuidados  de  saúde
primários;
Vigilância  sentinela
Escolhas  terapêuticas  iniciais  para  a hipertensão  arterial  na  Rede  de Médicos
Sentinela
Resumo
Introdução  e  objetivos:  Conhecer  os fármacos  escolhidos  para  tratar  os casos  incidentes  de
hipertensão arterial  ajuda  a  interpretar  o  uso  prevalente  de anti-hipertensores.  Procurámos
determinar  a  proporção  de doentes  que  inicia  tratamento  com  cada  classe  de  anti-
hipertensores,  que  médico  inicia  o tratamento,  se  os médicos  de família  alteram  prescrições
iniciadas  por  outros  e  comparar  padrões  de prescrição  de médicos  de família  e outros  especial-
istas.
Métodos:  Estudo  transversal  aninhado  na  coorte  da Rede  de Médicos  Sentinela  entre  2014  e
2015. Foram  notificados  casos  incidentes  de hipertensão  arterial  descrevendo  o tratamento,
quem fez  a  prescrição  inicial  e se  os  tratamentos  iniciados  por  outros  médicos  foram  alterados.
Resultados:  Notificados  681 casos  incidentes.  A  prescrição  inicial  foi feita  pelo  médico  de
família em  86,9%  (IC95%  84,2-89,3%)  dos  casos.  Os  agentes  mais  utilizados  foram  inibidores  da
enzima de  conversão  da  angiotensina  (51,3%,  IC95%  47,5-55,0%),  diuréticos  tiazídicos  (32,2%,
IC95% 28,8-35,8%)  e antagonistas  dos  recetores  da  angiotensina  (21,4%,  IC95%  18,5-24,7%).  Com-
parados com  outros  especialistas,  os  médicos  de  família  utilizaram  menos  beta-bloqueantes
(20,4  versus  5,9%,  p<0,001)  e diuréticos  de ansa  (8,2  versus  0,8%,  p=0,003).  As  prescrições
iniciadas  por  outros  foram  alteradas  em  11,6%  dos  casos  (IC95%  6,0-19,6%).
Conclusões:  Os inibidores  da  enzima  de conversão  da  angiotensina  foram  a  classe  mais  prescrita.
A maioria  dos  diagnósticos  foi feita  pelo  médico  de  família  do doente.  Os  médicos  de família
habitualmente  mantiveram  as  prescrições  iniciadas  por  outros  especialistas.  Os  padrões  de
prescrição de  médicos  de família  e  outros  especialistas  foram  semelhantes,  exceto  o  menor  uso
de beta-bloqueantes  e diuréticos  de ansa.
©  2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
direitos reservados.
Introduction
Following  the  trend  in developed  countries,  the prevalence
of  hypertension  in Portugal  is  rising  steadily.1 This  has led  to
a  near  doubling  in  the use  of  antihypertensive  drugs, in line
with  other  OECD  countries,  and  a  corresponding  increase  in
expenditure.2,3 A report  by  the  Portuguese  National  Author-
ity  for  Medicines  and Health  Products  (INFARMED)  found
growing  costs  were  mainly  attributable  to  greater  use  of
angiotensin  receptor  blockers  (ARBs),  despite  increased
use  of  generic  medicines.2 Compared  with  other  European
countries,  use  of  ARBs  was  higher  in Portugal,  with  almost
as  many  prescriptions  for  ARBs  in 2011  as  for  angiotensin-
converting  enzyme  (ACE)  inhibitors.  The  same  report  found
that  primary  care  physicians  were  the prescribing  source
for  76%  of  cardiovascular  medicines  dispensed  in outpa-
tient  pharmacies  in Portugal,  used  more  ARBs  than  hospitals
(although  less  than  physicians  in  private  practice),  and  pre-
scribed  as  many  generics  as  hospitals  and more  than  private
practice  physicians.  In  addition  to  their  higher  cost, ARBs  are
backed  by  weaker  evidence  than  ACE inhibitors  for  reducing
morbidity  and mortality,  although  they  are less  likely  to be
discontinued  due  to  adverse  effects.4,5
Portuguese  guidelines  recommend  thiazide  or  thiazide-
like  diuretics,  ACE inhibitors,  low-cost  ARBs,  long-acting
calcium  channel  blockers  (CCBs),  or  low-dose  low-cost
fixed-dose  associations  of  diuretics  with  ACE inhibitors  or
ARBs  as  first-line  therapy  for  patients  at low to  medium
cardiovascular  risk.6 For  patients  at high  cardiovascular
risk,  low-cost  fixed-dose  associations  of  thiazide  diuretics
or  CCBs  with  ACE  inhibitors  or  ARBs are recommended.
Beta-blockers  are also  considered  appropriate  as  initial
therapy  for younger  patients  and  those  with  coronary  heart
disease  and  certain  arrhythmias.  The  European  Society  of
Hypertension  and  European  Society  of Cardiology  guidelines
state  that  the  main  benefits  of  treating  hypertension  are
due  to  lowering  blood  pressure,  independently  of which
medicines  are used.7 Therefore,  thiazide  and thiazide-like
diuretics,  beta-blockers,  CCBs,  ACE  inhibitors  and  ARBs
are  all considered  appropriate  as  first-line  agents.  The
European  guidelines  recommend  lifestyle  changes  alone  for
young  individuals  with  isolated  elevation  of systolic  blood
pressure  and  as initial  treatment  for  patients  with  grade  I
hypertension  at low  to moderate  cardiovascular  risk.
Most  studies  on  antihypertensive  medication  prescribing
focus  on  prevalent  use.2,8--10 However,  this does  not  enable
conclusions  to  be drawn  about  how  physicians  choose  to
use  each medicine:  as  a  first-line  agent,  as  an  alternative
when  initial  therapy  results  in side  effects,  or  as  an  add-on
treatment  when  the  patient  fails  to  achieve  blood  pressure
goals.11 Focusing  on  incident  use  can  determine  which  drugs
are  chosen  as  first-line  treatment.
The  prescription  of ARBs and  thiazide  diuretics  has been
used  as  a quality  indicator  for  primary  care in  Portugal  since
2013.12 The  implicit  aim  was  to  decrease  ARB  use.  Although
family  physicians  issue  most  prescriptions,2 it is  not  known
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how  often  they  are  responsible  for  initiating  treatment  or
maintain  prescriptions  decided  by other  physicians.  Special-
ists  have  been  shown  to  influence  primary  care  physicians  by
being  earlier  adopters  of  new  drugs.13,14
Determining  how  antihypertensives  are  used to  initiate
treatment  and  who  is  responsible  for  their  prescription  can
help  guide  efforts  to  improve  quality  of  care  in the Por-
tuguese  National  Health  Service  (NHS).  If family  physicians
have  the  responsibility  for  initiating  treatment,  then  quality
indicators  targeting  them  may  change  how  antihyperten-
sives  are  used.  If,  however,  most  decisions  are made  by  other
physicians,  targeting  only  family  physicians  will  probably  be
ineffective.
With  this  study,  we  aimed  to  determine  the  proportion
of  patients  with  newly  diagnosed  hypertension  who  began
treatment  with  each  class  of antihypertensive  drug.  Sec-
ondary  objectives  were  to  determine  which physicians  were
responsible  for diagnosing  and  initiating  hypertension  treat-
ment  and  the  proportion  of  cases in which  family  physicians
altered  prescriptions  initiated  by  other  prescribers,  and  to
compare  the  prescribing  patterns  of family  physicians  with
those  of  other  specialists.
Methods
Study design  and  setting
The  Portuguese  NHS  is  a  publicly  funded single-payer  sys-
tem,  with  each  citizen  being  registered  in  a primary  care
practice  and  having  an  assigned  family  physician.15 Some  of
these  family  physicians  participate  as  volunteers  in the Por-
tuguese  Sentinel  Practice  Network,16 each of  whom  provides
a  cohort  of  their  registered  patients.  This  allows  the  network
to  maintain  an open  cohort  of  patients  that  is reasonably  sta-
ble  in  each  year  and  means  the incidence  of  health  problems
can  be  calculated  in this  sample  of  the Portuguese  popula-
tion.  The  network  was  set  up  to  conduct  weekly  surveillance
of  communicable  and  non-communicable  diseases,  and  has
also  been  used  for observational  epidemiological  research
to  answer  specific  questions  (satellite  studies).
Between  January  2014 and December  2015,  the  network
expanded  the  information  being  reported  on  the  incidence
of  hypertension  for  surveillance  purposes,  to  conduct  a  con-
tinuous  notification  cross-sectional  study  among  new  cases
of  hypertension  notified  in the cohort.
Participants
In  2014  and 2015  the  population  under  observation
consisted  of 35 535  individuals,  distributed  between  82
family  physicians  participating  in the  Portuguese  Sen-
tinel  Practice  Network.  Participating  physicians  were  asked
to  notify  all  incident  cases  of  hypertension.  Hyperten-
sion  was  defined  using  the  criteria  adopted  by the
Portuguese  Directorate-General  of  Health  (DGS)  (systolic
blood  pressure  of  140 mmHg  or  higher  or  diastolic  blood
pressure  of  90  mmHg  or  higher  on  several  separate
occasions).17
Measurements
Data  were  collected  using  paper  or  online  forms.  Notifi-
cations  included  information  on  patient  age at diagnosis,
gender,  pharmacological  treatment  (entered  in a free  text
field  on  the paper  form, which  was  subsequently  coded  by
the  investigators  as  the international  nonproprietary  name;
the online  form  had  a  list  of  antihypertensive  drugs  available
on  the Portuguese  market  by  international  nonproprietary
name,  of which up  to  three  could  be  entered),  other  treat-
ment  measures  (free  text field),  who  had  issued  the initial
prescription  (the  family  physician  participating  in the  sen-
tinel  practice  network  or  a  different  physician,  who  was
then  specified  in a separate  free  text  field; these  were  sub-
sequently  divided  in two  categories:  family physicians  and
other  specialists),  and,  for  prescriptions  initiated  by  other
physicians,  whether  the  notifying  physician  had changed
the  treatment.  The  Sentinel  Practice  Network  coordinating
team  followed  up any  submissions  with  incomplete  or  unin-
telligible  information,  contacting  the notifying  physician  to
gather  missing  data.
Outcomes
The  main  outcome  in  this study  was  the proportion  of
patients  who  began  treatment  with  each class  of  antihy-
pertensive  drug.  Classes  were defined using the  Anatomical
Therapeutic  Chemical  classification  for  antihypertensives
(C02),  diuretics  (C03),  beta-blocking  agents  (C07),  CCBs
(C08),  and  agents  acting  on  the renin-angiotensin  system
(C09).18
Secondary  outcomes  were  the proportion  of  patients  for
whom  initial  diagnosis and  prescription  of  therapy  were
by  family  physicians  (those  participating  in the  Sentinel
Practice  Network  or  other  family medicine  specialists)  or  by
other  specialists  (hospital  and  private  based);  the  proportion
of  patients  for  whom  Sentinel  Practice  Network  physicians
altered  prescriptions  initiated  by  others; and  the  proportion
of  each  class  of  antihypertensive  drugs  prescribed  by  family
physicians  as  opposed  to  other  specialists.
Drugs  were  compared  regarding  use  as  single  treatment
combinations  in a given  patient  and  total  use  (as  part of
any  combinations  of  antihypertensive  therapy  --  alone,  in
fixed-dose  associations  or  combined  with  the administration
of other  drugs as separate  pills).
Study size
To  estimate  the proportion  of  patients  beginning  treatment
with  each  class  of  antihypertensive  drug  with  5% precision
and  95%  confidence,  assuming  as  a worst-case  scenario  that
50%  of  patients  would  begin  with  a  given  class,  a minimum
sample  size  of  384  cases  of  hypertension  was  calculated.
Given  the notification  rates in previous  years  of  206 new
cases  of hypertension  per  year,  we  estimated  that two  years
of  continuous  notifications  would  be needed  to  achieve  our
target  sample  size.
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Statistical  analysis
Proportions  of  each  antihypertensive  class  prescribed  as
initial  therapy  were  estimated  with  the respective  95%  confi-
dence  interval  (CI).  Patient  distribution  regarding  gender
among  family  physicians  and other  specialists  was  com-
pared  using  Fisher’s exact  test  and age distribution  was
compared  using  the t  test.  Prescription  patterns  of  family
physicians  and  other  specialists  were  compared  using  mul-
tivariate  logistic  regression  analysis  adjusting  for  patient
gender  and  age.  A level  of  significance  ()  of  0.01  was  used
as  the  threshold  for  statistical  significance  to  account  for
multiple  comparisons.
Ethical  approval
The  study  was  approved  by  the  Ethics  Committee  of  the
Portuguese  National  Health  Institute  Doutor  Ricardo  Jorge.
Results
Between  2014  and  2015,  72  family  physicians  participat-
ing  in the  Portuguese  Sentinel  Practice  Network  notified
681  new  cases  of  hypertension.  Ten  participants  did  not
provide  any  hypertension  notifications,  but  notified  other
health  conditions,  hence  their  patient  lists  were  included
to  estimate  incidence.  Hypertension  incidence  in the cohort
was  9.6/1000  person-years.  Mean  age  at  diagnosis  was  57.0
years  (standard  deviation  13.2),  and  50.1%  of  patients  were
male.
Initial  diagnosis  and  prescription  were  by  the  patient’s
family  physician  in 592 cases  (86.9%,  95%  CI: 84.2-89.3%),
other  family  physicians  in  21  cases  (3.1%,  95%  CI:  2.0-4.7%),
other  specialists  in 49  cases  (7.2%,  95%  CI:  5.5-9.4%)  and
physicians  with  unknown  specialty  in 19  cases  (2.8%,  95%
CI:  1.8-4-3%).  There  were  no  statistical  differences  between
family  physicians  (Sentinel  Practice  Network  participants
and  other  family  physicians)  and  other  specialists  (exclud-
ing  unknown  specialty)  regarding  patient  age  (56.7  vs.  60.4
years,  p=0.058)  or  gender  (49.1  vs.  59.2%  male,  p=0.19).
Pharmacological  treatment  was  initiated  in  95.5%  (95%
CI: 93.6-96.8%)  of  cases,  while  lifestyle  changes  alone  were
introduced  in  4.4%  (95%  CI: 3.1-6.2%)  and no treatment
was  reported  in  one  notification.  Among  patients  who  were
prescribed  drugs,  lifestyle  changes  were  also  prescribed  in
50.1%  (95%  CI: 46.3-54.0%).
A  single  drug  was  used  in 68.3%  (95%  CI: 64.6-71.8%)
of  patients  who  were prescribed  medication,  two  drugs in
30.3%  (95%  CI: 26.9-34.0%)  and three  drugs  in 1.4%  (95%  CI:
0.7-2.7%).  No  significant  differences  were  found  between
family  physicians  and  other  specialists  in the  use  of  a single
drug compared  with  two  or  more  (69.5  vs.  53.1%  of  patients,
p=0.025).
Fixed-dose  associations  were  used  in 27.9%  (95%  CI: 24.5-
31.4%)  of  patients  who  were  prescribed  pharmacological
treatment.  No  differences  were  seen  in the use  of  fixed-dose
associations  between  family  physicians  and other  specialists
(27.6  vs.  32.7%  of  patients,  p=0.45).
The  proportions  of  each class  of antihypertensive  agents
prescribed  as  initial therapy  are shown  in  Table  1  (treatment
combinations)  and Table  2 (total  use  of  each  pharmaco-
logical  class).  ACE  inhibitors  were  the drugs  most  often
prescribed,  both  as  single  treatment  (31.4%  of  patients)  and
in  total  (51.3%).  Lisinopril  was  the most used  ACE (32.4%
of  the  class),  followed  by  perindopril  (26.1%)  and  ramipril
(21.2%).  There  were  no  differences  between  family  physi-
cians  and  other  specialists  in the use  of ACE inhibitors  as
single  treatment  (p=0.38)  (Table  1)  or  in total  (p=0.81)
(Table 2).
Thiazide  and  thiazide-like  diuretics  were the second
most  used  drugs,  with  hydrochlorothiazide  leading  the  class
(43.9%;  always  used  as  part  of  fixed  associations  as  it  is  not
available  as a single  agent  in the Portuguese  market),  fol-
lowed  by  indapamide  (39.4%)  and chlorthalidone  (16.7%).
No  differences  were  found  in the  use  of  thiazide-like  diuret-
ics as single  treatment  (p=0.032)  or  in total  use  (p=0.16)
between  family physicians  and  other  specialists.
ARBs  were  the  third  most  used  drugs  as  single  treatment
(Table 1)  and in total  (Table  2), with  losartan  being  used
most  often  (30.8%  of  class),  followed  by  olmesartan  (20.5%),
valsartan  (17.8%)  and  telmisartan  (15.1%).  There  were  no
Table  1  Proportion  of  patients  prescribed  each  combination  of  antihypertensive  treatment,  by  class  and type  of  physician.
Initial  therapy  Family  physicians
(n=613)
Other  specialists  (n=49)  Specialty  unknown  (n=19)  Total  (n=681)
%  (95%  CI)
Lifestyle  changes  alone  4.7  (3.3-6.7)  0.0  (0.0-8.7)  5.3  (0.0-26.5)  4.4  (3.1-6.2)
ACE inhibitor  31.8  (28.3-35.6)  26.5  (16.1-40.4)  31.6  (15.2-54.2)  31.4  (28.1-35.0)
Thiazide-like diuretic  15.3  (12.7-18.4)  2.0  (0.0-11.7)  10.5  (1.7-32.6)  14.2  (11.8-17.1)
ARB 11.9  (9.6-14.7)  10.2  (4.0-22.2)  15.8  (4.7-38.4)  11.9  (9.7-14.6)
ACE inhibitor  and  thiazide  diuretic  10.3  (8.1-13.0)  6.1  (1.5-17.2)  21.1  (8.0-43.9)  10.3  (8.2-12.8)
ACE inhibitor  and  CCB  7.7  (5.8-10.1)  12.2  (5.4-24.6)  0.0  (0.0-19.8)  7.8  (6.0-10.1)
ARB and  thiazide  diuretic  6.2  (4.5-8.4)  12.2  (5.4-24.6)  5.3  (0.0-26.5)  6.6  (5.0-8.7)
Beta-blocker 4.7  (3.3-6.7)  12.2  (5.4-24.6)  5.3  (0.0-26.5)  5.3  (3.8-7.3)
CCB 2.1  (1.2-3.6)  2.0  (0.0-11.7)  0.0  (0.0-19.8)  2.1  (1.2-3.5)
ARB and  CCB  2.1  (1.2-3.6)  2.0  (0.0-11.7)  0.0  (0.0-19.8)  2.1  (1.2-3.5)
Other 3.1  (2.0-4.8)  14.3  (6.8-27.0)  5.3  (0.0-26.5)  4.0  (2.7-5.7)
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CI: confidence interval.
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Table  2  Proportion  of  patients  who  were  prescribed  each  class  of  antihypertensive  drugs,  by  type  of  physician.
Initial  therapy  Family  physicians  (n=613)  Other  specialists  (n=49)  Specialty  unknown  (n=19)  Total  (n=681)
%  (95%  CI)
ACE  inhibitor  51.2  (47.3-55.2)  51.0  (37.5-64.4)  52.6  (31.7-72.7)  51.3  (47.5-55.0)
Thiazide-like  diuretica 32.8  (29.2-36.6)  22.5  (12.9-36.0)  36.8  (19.1-59.1)  32.2  (28.8-35.8)
ARB 20.7  (17.7-24.1)  30.6  (19.4-44.6)  21.1  (8.0-43.9)  21.4  (18.5-24.7)
CCB 13.1  (10.6-16.0)  18.4  (9.8-31.6)  0.0  (0.0-19.8)  13.1  (10.7-15.8)
Beta-blocker  5.9  (4.3-8.0)  20.4  (11.3-33.8)  5.3  (0.0-26.5)  6.9 (5.2-9.1)
Loop diuretic 0.8  (0.3-2.0) 8.2  (2.7-19.7) 0.0  (0.0-19.8) 1.3  (0.1-2.5)
Potassium-sparing  diuretic 0.3  (0.0-1.3) 0.0  (0.0-8.7) 0.0  (0.0-19.8) 0.3  (0.0-1.1)
Renin inhibitor 0.0  (0.0-0.8) 0.0  (0.0-8.7) 0.0  (0.0-19.8) 0.0  (0.0-0.7)
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CI:  confidence interval.
a Includes thiazide diuretics.
differences  between  family  physicians  and  other  specialists
regarding  single  (p=0.88)  or  total  use  (p=0.081).
CCBs were  rarely used  as  single  treatment  (2.1%  of
patients),  but  they  were the  fourth  most used  class  in total
(13.1%),  with  amlodipine  being the most prescribed  (51.1%
of  class).  Again,  no  differences  were seen  between  family
physicians  and  other  specialists  (p=0.93  for single  use  and
p=0.44  for  total  use).
Beta-blockers  were used  by  family  physicians  less than
other  specialists,  both  as  single  treatment  (4.7 vs.  12.2%,
p=0.007)  and  in total  (5.9  vs.  20.4%  of  patients,  p<0.001).
Bisoprolol  was  the  most prescribed  beta-blocker  (44.7%  of
class).
Total  use  of loop  diuretics  was  also  lower  in primary
care  physicians  (0.8 vs.  8.2%,  p=0.003).  Loop  diuretics  were
used  as  single  treatment  in only one  case.  Potassium-sparing
diuretics  were  not  reported  as  single  initial  treatment,  and
were  used  in combination  with  other  antihypertensives  in
only  two  cases.  Direct  renin  inhibitors  were not  used  as  part
of  the  initial  treatment  for hypertension.
In  the  89  cases  in which  treatment  was  not  initiated
by  physicians  participating  in the Sentinel  Practice  Net-
work,  there  was  a  change  in pharmacological  treatment  in
10  patients  (11.6%, 95%  CI:  6.0-19.6%)  and information  was
missing  for  three  patients  (3.4%).
Discussion
Main  findings
The  clear  majority  of  patients  with  newly  diagnosed
hypertension  were  prescribed  pharmacological  treatment.
Two-thirds  of  patients  were  started  on  a single  drug,  with
physicians  preferring,  in decreasing  order,  ACE  inhibitors,
thiazide-like  diuretics  and  ARBs.  Most patients  who  were
prescribed  more  than  one drug  were  started  on  fixed  associa-
tions,  of which  ACE  inhibitors  with  thiazide  diuretics  or  with
CCBs  were  preferred.  Loop  and potassium-sparing  diuretics
were  rarely  prescribed  in  first-line treatments,  and  there
were  no  reports  of  the  use  of  direct  renin  inhibitors.
Most  diagnoses  were  made  by  the patient’s  family  physi-
cian.  Family  physicians  did not  differ  significantly  from  other
specialists  regarding  the  use  of  most  classes  of antihyperten-
sives,  but  used  less  beta-blockers  and  loop  diuretics.  When
other  specialists  initiated  therapy,  it  was  usually  continued
by  family  physicians.
Strengths  and limitations
By  prospectively  collecting  data  within  the  Sentinel  Practice
Network  cohort,  we  were  able  to  gather  accurate  data
regarding  drugs  being  prescribed  for new  cases  of  hyperten-
sion,  avoiding  recall  bias  and administrative  inaccuracies.
In  most  cases,  the physician  reporting  the  case  was  the one
who  had  made  the  diagnosis  and  therapeutic  decision  a few
moments  before.  For cases  in which  the diagnosis  had  been
made  by  other  physicians,  information  was  gathered  from
patients  when  they  visited  their  family  physicians  to  request
refill  prescriptions  or  for other  medical  problems.  If needed,
additional  information  could  be gathered  from  the patient’s
national  record,  which allows  the  family  physician  to  view
details  of  prescriptions  issued  elsewhere,  including  by  hospi-
tal  and  private  physicians  (electronic  prescription  has  been
mandatory  since  August  2011  to  be  eligible  for reimburse-
ment  by  the Portuguese  National  Health  Service).19 Having
this  information  available  to  Sentinel  physicians  greatly
reduced  patient  recall  bias  in our  study.
Some  patients  may  have  been  diagnosed  with  hyperten-
sion  by  other  physicians  and not  visited  their  family physician
during  the  study  period,  and were  therefore  not  reported
to the Sentinel  Practice  Network.  Hence,  the incidence  of
hypertension  may  be  underestimated  and  the proportion  of
diagnoses  made  by family  physicians  may  be  overestimated
in  our  study.  However,  hypertension  incidence  was  similar  to
that  reported  previously  in the Sentinel  Practice  Network,20
and  by  authors  in other  settings.21 This  suggests  that  under-
reporting  was  low.
The  study  did not  collect  data  on  disease  severity,  the
presence  of  comorbidities  or  contraindications  to  specific
drugs.  These  could  influence  the choice  of initial treatment,
particularly  under  Portuguese  guidelines.  However,  gather-
ing such  information  would  have  increased  the  amount  of
time  physicians  had to  dedicate  to  each  notification  and
the  space  needed  on  the paper  notification  forms.  Both
would  make  the  study  unacceptable  to  the Sentinel  Practice
Network.  We  cannot  exclude  the  possibility  that  patients
with  more  severe  clinical  conditions  on  initial  presentation,
such  as  acute  cardiovascular  events  or  heart  failure,  were
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more  often  seen  and managed  by  specialists  than  by fam-
ily  physicians.  This  may  explain  the higher  prescription  of
beta-blockers  and loop diuretics.
Yet  these  differences  between  family  physicians  and
other  specialists  must  be  taken  as  hypothesis-generating
only.  The comparison  of  prescribing  patterns  was  a  sec-
ondary  outcome  in our  study  and  multiple  comparisons  were
made.  Despite  having  used  a statistical  threshold  of  0.01
instead  of  0.05  for  significance  to  account for  multiple  test-
ing,  it  is still  possible  that  these  differences  represent  false
positive  results.  We  did  not  define  a  formal  adjustment
method  for  multiple  comparisons  in the  study’s  methods
since  we  could  not  have known how  many  combinations  of
antihypertensive  treatments  would  be  present  in our  sam-
ple.  There  may  also  have  been  other  differences,  but  our
study  was  underpowered  to find  them.
Although  not statistically  significant,  there  were  large
absolute  differences  between  family  physicians  and  other
specialists  in the  proportion  of men  diagnosed,  mean  age
at  diagnosis,  and  the proportion  of  patients  treated  with
a  single  drug.  Our  study  may  have  been underpowered  to
find  these  differences,  as  there  were  relatively  few  cases
diagnosed  by  other  specialists.
Another  limitation  is  that  physicians  who  volunteer  to
participate  in  the  Sentinel  Practice  Network  may  be  dif-
ferent  from other  family physicians,  resulting  in  different
prescribing  patterns.  However,  other  authors  have  found
these  differences  to  be  small.22,23 Also,  given  that  the
observed  prescribing  patterns  for  Sentinel  physicians  and
other  specialists  were  similar,  it is  unlikely  that  they  differ
significantly  from  those  of  other  family  physicians.
Interpretation  of results
Previous  research  on  prevalent  use  of antihypertensives  had
reported  greater  use  of  multiple  agents,  of  ARBs relative  to
ACE  inhibitors,  and  of  diuretics,  CCBs  and beta-blockers.8,24
Greater  use  of  combination  therapy  than  in our  study  is  to
be  expected,  since  an  analysis  of prevalent  use  will  include
patients  with  longer  disease  duration.  More  use  of  diuretics,
CCBs  and  beta-blockers  may  be  explained  by  the use  of
these  agents  mainly as  add-on  therapy  when blood  pressure
goals  are  not  achieved.  Our  study  showed  that  ACE  inhibitors
were  used  almost  two  and a  half  times  more  than  ARBs  for
initial  treatment.  This  is  different  from  what  was  observed
in  previous  studies  on  prevalent  use  and administrative
data  on  drug  dispensing,  in which ACE  inhibitors  were  used
less  often  than  ARBs.2,8,24 Since  ACE  inhibitors  and  ARBs  are
seldom  used  in combination  in  the  same  patient,  comparing
prevalent  use  can  approximate  the relative  proportion  of
patients  treated  with  each  of them.  Lower  prevalent  use  of
ACE  inhibitors  may  indicate  that, after  initiating  treatment,
a  significant  proportion  of patients  substitute  them  for
other  classes  like ARBs.  It  is also  possible  that  prescription
patterns  have  changed  since  the previous  studies  and
physicians  are  now  preferring  ACE inhibitors  over  ARBs.
Participants  in  the Sentinel  Practice  Network  usually  did
not  alter  prescriptions  issued  by  other  physicians.  This  may
be  because  they agree  with  the  prescription,  as  our  results
show  no  major  differences  in prescribing  patterns  between
family  physicians  and  other  specialists.  It  is  also  possible  that
family  physicians  feel  they  do not have  enough  information
to  change  prescriptions  initiated  by  specialists,  the patient
will  continue  under  the  responsibility  of  the  other  physician,
or  the patient  would  be  resistant  to  change.25
Implications  for practice  and research
Pharmacological  treatment  employed  a  large  variety  of
drugs  of  different  classes,  and  both  family physicians  and
specialists  appear  to  be following  Portuguese  and  European
hypertension  guidelines  for  treating  new  patients.6,7 Since
use  of  ARBs  is much  lower  in incident  than  in  prevalent
patients,  future  studies  should focus  on  how  drugs  are  used
after  the initial  diagnosis,  particularly  if ARBs  are  introduced
because  of  adverse  reactions,  as  substitutes  or  as  add-on
treatment  due  to  failure  of  blood  pressure  control  with  ini-
tial  therapy  or  for  other  reasons.  If  Portugal  is  to  reduce  use
of  ARBs,  guidelines  should  include  further  recommendations
on  how  to  manage  patients  who  are not  adequately  con-
trolled  or  who  experience  adverse  reactions  with  the  drugs
initially  prescribed.
Family  physicians  and  specialists  had similar  prescribing
patterns,  but  the  former  were the main  initiators  of  antihy-
pertensive  treatment.  Therefore,  efforts  to  improve  quality
of  care  in  treating  hypertension  should  be  mainly  directed
at  family  physicians.
Conclusions
The most  used  drug classes  in  incident  cases  of  hypertension
were,  in decreasing  order,  ACE inhibitors,  thiazide  diuretics
and  ARBs.  Most  patients  were diagnosed  by the  patients’
family  physician,  but  when  they  were  not,  in most  cases
family  physicians  opted  to  maintain  treatments  initiated  by
other  physicians.  Prescribing  patterns  were  similar  between
family  physicians  and  other  specialists  except  for  lower  use
of  beta-blockers  and loop  diuretics.
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